Artelo Biosciences Inc ARTL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ARTL is a good fit for your portfolio.
News
-
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
-
Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
-
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
-
Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge
-
Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th
Trading Information
- Previous Close Price
- $1.30
- Day Range
- $1.26–1.34
- 52-Week Range
- $1.15–2.98
- Bid/Ask
- $1.31 / $1.33
- Market Cap
- $4.23 Mil
- Volume/Avg
- 15,876 / 15,836
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.artelobio.com
Valuation
|
Metric
|
ARTL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.36 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ARTL
|
|---|---|
Quick Ratio | 8.08 |
Current Ratio | 8.51 |
Interest Coverage | — |
Quick Ratio
ARTL
Profitability
|
Metric
|
ARTL
|
|---|---|
Return on Assets (Normalized) | −52.83% |
Return on Equity (Normalized) | −55.94% |
Return on Invested Capital (Normalized) | −55.79% |
Return on Assets
ARTL
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jzcdlswc | Qxxl | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jcqrntlsp | Wqnllzx | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Sjvrfsyl | Qmccl | $98.8 Bil | |
MRNA
| Moderna Inc | Ydzjsnxgj | Qjm | $38.8 Bil | |
ARGX
| argenx SE ADR | Gvlsrfb | Trggr | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Nmggvlst | Vxmyy | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jyphjgc | Mwzkbh | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Cglmbzp | Wzpfdj | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bdkbhnypf | Tccwbm | $12.4 Bil | |
INCY
| Incyte Corp | Nkvpfzhkl | Gygrlm | $11.9 Bil |